Progyny Reports Record Q3 2026 Results and Raises Full-Year Guidance
Progyny, Inc. (PGNY) delivered strong third-quarter 2026 financial results, characterized by an 8.9% year-over-year revenue increase to $341.3 million. The company achieved a record-breaking selling season, adding 1.3 million new covered lives and over 85 new clients, which is expected to drive total covered lives to 8.3 million in 2027. Profitability saw significant improvement, with net income rising to $26.3 million ($0.32 per diluted share) compared to $13.9 million in the prior year period. Gross margins expanded by 130 basis points due to care management efficiencies and reduced stock-based compensation. Following these results, management raised its full-year revenue guidance to a range of $1.365 billion to $1.385 billion.
Tickers: $PGNY
Topics: fertility benefit services financial guidance net income increase pharmacy benefit services revenue growth